Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Metrics to compare | NVV1 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVV1PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.7x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 1.6x | 2.6x | |
Price / LTM Sales | 0.0x | 6.2x | 3.1x | |
Upside (Analyst Target) | 0.0% | 176.3% | 55.7% | |
Fair Value Upside | Unlock | 11.6% | 6.8% | Unlock |